Get started
Author

Ingrid Jyssum

Observed names: I Jyssum, I. Jyssum, Jyssum, Ingrid, ingrid Jyssum
ORCID: 0000-0003-1412-9713
Observed ORCID: 0000-0003-1412-9713
OpenAlex ID: A5072837330
Immunogenicity and Safety of Standard and Third‐Dose SARS – CoV ‐2 Vaccination in Patients Receiving Immunosuppressive Therapy
2022 · Silje W. Syversen, Ingrid Jyssum, et al. · Arthritis & Rheumatology · 58
PDF
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
2023 · Ingrid Jyssum, Johanna E Gehin, et al. · Rheumatology · 33
PDF
Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy
2022 · Silje Watterdal Syversen, Ingrid Jyssum, et al. · RMD Open · 29
PDF
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
2022 · Kristin H Bjørlykke, Hilde S Ørbo, et al. · The Lancet Rheumatology · 25
PDF
The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study
2022 · Ingrid Egeland Christensen, Ingrid Jyssum, et al. · BMC Medicine · 18
PDF
T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients on TNF inhibitor treatment: a prospective cohort study
2024 · Asia-Sophia Wolf, Kristin H. Bjørlykke, et al. · EBioMedicine · 14
Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study
2024 · Hilde S Ørbo, Kristin H Bjørlykke, et al. · RMD Open · 7
PDF
Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study
2024 · Hassen Kared, Ingrid Jyssum, et al. · Frontiers in Immunology · 7
PDF
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
2024 · Johanna Elin Gehin, Rolf Anton Klaasen, et al. · RMD Open · 6
PDF
Humoral immune response to SARS-CoV-2 vaccination in patients with inflammatory bowel disease on immunosuppressive medication: association to serum drug levels and disease type
2023 · Kristin Kaasen Jørgensen, Marte Lie Høivik, et al. · Scandinavian Journal of Gastroenterology · 3
PDF
Immune response and safety in standard and third dose SARS-CoV-2 vaccination in patients with autoimmune hepatitis on immunosupressive therapy, a prospective cohort study
2022 · Kristin Jorgensen, Adity Chopra, et al. · Journal of Hepatology · 2
PDF
Humoral and cellular responses to a fifth bivalent SARS-CoV-2 vaccine dose in patients with immune-mediated inflammatory diseases on tumour necrosis factor inhibitors: a prospective cohort study
2024 · Hilde S. Ørbo, Taissa de Matos Kasahara, et al. · The Lancet Regional Health - Europe · 1
AB1353 SAFETY OF UPDATED XBB.1.5 SARS-CoV-2 VACCINE BOOSTERS IN PATIENTS WITH INFLAMMATORY JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPIES
2024 · H.S. Ørbo, I. Jyssum, et al. · Annals of the Rheumatic Diseases · 1
P1056 T cell responses to repeated SARS-CoV-2 vaccination and breakthrough infections in patients with inflammatory bowel disease on TNF inhibitor treatment, a prospective cohort study
2024 · K H Bjørlykke, A S Wolf, et al. · Journal of Crohn s and Colitis · 1
PDF
Pos0252 Differences in Serum Drug Levels and Anti-drug Antibodies in Patients With Inflammatory Arthritis Treated With Originator Vs Biosimilar Adalimumab
2023 · I. Jyssum, J. E. Gehin, et al. · Annals of the Rheumatic Diseases · 1
PDF
OP0192 SEROLOGICAL RESPONSE AND SAFETY OF A THREE-DOSE SARS-CoV-2 VACCINATION STRATEGY IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES ON IMMUNOSUPPRESSIVE THERAPY
2022 · I. Jyssum, A.T. Tveter, et al. · Annals of the Rheumatic Diseases · 1
PDF
P605 Immunogenicity and safety of standard and third dose SARS-CoV-2 vaccination in patients with immune-mediated inflammatory diseases; a prospective cohort study
2022 · K K Jørgensen, S W Syversen, et al. · Journal of Crohn s and Colitis · 1
The Effect of Certolizumab Pegol Dose and Dose Changes on Plasma Trough Levels: Data From a Randomized Phase III Trial
2026 · Johanna E. Gehin, Rolf A. Klaasen, et al. · Therapeutic Drug Monitoring
Abs1163 Personalised Adalimumab Therapy: Development of an Algorithm for Therapeutic Drug Monitoring
2025 · I. Jyssum, J.E. Gehin, et al. · Annals of the Rheumatic Diseases
POS0573 NEUTRALISING ANTIBODY RESPONSES TO BIVALENT SARS-CoV-2 VACCINES AND HYBRID IMMUNITY IN PATIENTS ON TNF INHIBITORS: A PROSPECTIVE COHORT STUDY
2024 · H.S. Ørbo, T.M. Kasahara, et al. · Annals of the Rheumatic Diseases
POS0090 CELLULAR AND HUMORAL RESPONSES RESTORED BY UPDATED SARS-CoV-2 VACCINES AND HYBRID IMMUNITY IN PATIENTS ON TNF INHIBITORS: A PROSPECTIVE COHORT STUDY
2024 · H.S. Ørbo, A.S. Wolf, et al. · Annals of the Rheumatic Diseases
AB0070 DURABILITY OF CELLULAR AND HUMORAL IMMUNITY FOLLOWING A FIFTH SARS-CoV-2 VACCINE IN PATIENTS WITH INFLAMMATORY JOINT DISEASES ON IMMUNOSUPPRESSIVE THERAPIES
2024 · H.S. Ørbo, I. Jyssum, et al. · Annals of the Rheumatic Diseases
Immunogenicity of therapeutics in inflammatory joint- and bowel diseases
2024 · Jyssum, Ingrid · NORA - Norwegian Open Research Archives
Op0085 Longitudinal T Cell Responses to a Series of Four Sars-cov-2 Vaccine Doses or Covid-19 in Patients on Tnf Inhibitors
2023 · H. Ørbo, A.S.F.M. Wolf, et al. · Annals of the Rheumatic Diseases
PDF
Op0080 Incidence and Clinical Outcome of Covid-19 Related to Post-vaccination Antibody Levels in Patients on Immunosuppressive Therapy: a Prospective Study in the Omicron Era
2023 · H. Ørbo, K.H. Bjørlykke, et al. · Annals of the Rheumatic Diseases
PDF
Works count: 34
Citation count: 208
H-index: 7
I10-index: 6
Year
Topic
Type